Argá Medtech Secures €54 Million Series B Funding to Revolutionize Cardiac Arrhythmia Treatment

Argá Medtech, a pioneering Swiss company developing a transformative cardiac ablation system, has secured €54 million in Series B funding. This significant investment fuels the company’s mission to revolutionize the treatment of cardiac arrhythmias, a prevalent condition affecting millions globally.

Understanding the Funding Landscape:

The global cardiac ablation market is expected to reach a staggering $5.3 billion by 2027 (attached report here: GrandView Research). This growth is driven by the rising prevalence of cardiac arrhythmias, increasing technological advancements, and growing awareness of minimally invasive treatment options.

Argá Medtech’s Innovative Approach:

Argá Medtech’s core offering is the CSE™ Pulsed Field Ablation (PFA) system, designed to treat atrial fibrillation (AF), a common type of cardiac arrhythmia. The system leverages coherent sine-burst electroporation™ (CSE™) technology to create durable lesions in heart tissue with greater precision and control compared to traditional ablation methods.

Key Advantages of the CSE™ PFA System:

  • Versatility: The catheter design allows for the creation of circular, linear, and focal lesions, catering to various arrhythmia patterns.
  • Energy Control: The CSE™ PFA waveform enables titration of energy delivery based on tissue depth, minimizing the risk of collateral damage.
  • Clinical Validation: Argá Medtech has successfully conducted a 48-patient first-in-human study in Europe, demonstrating the system’s efficacy and safety in treating AF.

Funding to Fuel Growth:

The Series B funding will empower Argá Medtech to:

  • Advance clinical development: The company plans to initiate an Investigational Device Exemption (IDE) study in the US and a CE Mark study in the EU to obtain regulatory approvals for its CSE™ PFA system.
  • Expand US presence: With a focus on upcoming US clinical activities, Argá Medtech will expand its offices in San Diego, CA.

Deal Highlights:

Existing Investors: Advent Life Sciences, Earlybird HealthSeries B€54 Million
New Investors: Gilde Healthcare, Undisclosed InvestorSeries B€54 Million (Breakdown not publicly disclosed)

Argá Medtech‘s innovative technology, coupled with this substantial funding, positions them at the forefront of transforming cardiac arrhythmia treatment. As they navigate the clinical development process and expand their presence, Argá Medtech holds immense potential to improve the lives of millions suffering from this debilitating condition.

Related Posts